Wireless Telecommunications Bureau and Wireline Competition Bureau (the Bureaus) may implement, and (3) certify its challenge. The USAC system will validate a challenger's evidence using an automated challenge validation process. Once all valid challenges have been identified, a challenged party that chooses to respond to any valid challenge(s) may submit additional data via the online USAC portal during the established response window. A challenged party may submit technical information that is probative regarding the validity of a challenger's speed tests, including speed test data and other device-specific data collected from transmitter monitoring software or, alternatively, may submit its own speed test data that conforms to the same standards and requirements specified by the Commission and the Bureaus for challengers.

In conjunction with the qualified 4G LTE data separately collected pursuant to OMB 3060-1242 that will be used to create the map of areas presumptively eligible for MF-II support, the information collected under this MF-II challenge process collection will enable the Commission to efficiently resolve disputes concerning the eligibility or ineligibility of an area initially deemed ineligible for MF-II support and establish the final map of areas eligible for such support, thereby furthering the Commission's goal of targeting MF-II support to areas that lack adequate mobile voice and broadband coverage absent subsidies through a transparent process.

The Commission received approval from OMB for the information collection requirements contained in OMB 3060–1251 on February 7, 2018.

Federal Communications Commission.

### Marlene H. Dortch,

Secretary, Office of the Secretary. [FR Doc. 2018–03000 Filed 2–13–18; 8:45 am]

BILLING CODE 6712-01-P

### FEDERAL ELECTION COMMISSION

## **Sunshine Act Meeting**

TIME AND DATE: Thursday, February 15, 2018 at 10:00 a.m.

**PLACE:** 999 E Street NW, Washington, DC (Ninth Floor).

**STATUS:** This Meeting, open to the public, has been cancelled.

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer, Telephone: (202) 694–1220.

Signed:

#### Dayna C. Brown,

Secretary and Clerk of the Commission. [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm]

BILLING CODE 6715-01-P

# **FEDERAL RESERVE SYSTEM**

# Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 7, 2018.

- A. Federal Reserve Bank of Atlanta (Kathryn Haney, Director of Applications) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to Applications.Comments@atl.frb.org:
- 1. Brandt J. Dufrene, Sr., individually and as trustee for The FSC Trust No. 1, and Brandt J. Dufrene, Jr., individually and as the trustee for The FSC Trust No. 2 and the Brandt J. Dufrene, Jr. Trust No. 1, all of Metairie, Louisiana; to retain voting shares of First St. Charles Bancshares, Inc., and thereby indirectly retain First National Bank USA, both Boutte, Louisiana.

Board of Governors of the Federal Reserve System, February 9, 2018.

#### Ann E. Misback,

Secretary of the Board.

[FR Doc. 2018–03082 Filed 2–13–18; 8:45 am]

BILLING CODE P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

[CDC-2018-0004; NIOSH-233-B]

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings: Proposed Additions to the NIOSH Hazardous Drug List 2018

**AGENCY:** Centers for Disease Control and Prevention, HHS.

**ACTION:** Notice of draft document available for public comment.

SUMMARY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability for public comment on the drugs proposed for placement on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2018 (List), as well as the NIOSH Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.

**DATES:** Comments must be received by April 16, 2018.

**ADDRESSES:** Comments may be submitted, identified by docket numbers CDC-2018-0004 and NIOSH-233-B, by either of the following two methods:

- Federal eRulemaking Portal: www.regulations.gov. Follow the instructions for submitting comments.
- *Mail*: NIOSH Docket Office, Robert A. Taft Laboratories, MS–C34, 1090 Tusculum Avenue, Cincinnati, OH 45226–1998.

Instructions: All information received in response to this notice must include the agency name and the docket numbers (CDC–2018–0004; NIOSH–233–B). All relevant comments received will be posted without change to www.regulations.gov, including any personal information provided.

#### FOR FURTHER INFORMATION CONTACT:

Barbara MacKenzie, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C26, Cincinnati, OH 45226, telephone (513) 533–8132 (not a toll free number), Email: hazardousdrugs@cdc.gov.

#### SUPPLEMENTARY INFORMATION:

#### I. Public Participation

Interested parties are invited to participate in this action by submitting written views, opinions, recommendation, and/or data. Comments are invited on any topic related to the drugs identified in this notice, including those evaluated for